Lexaria Bioscience Corp. (LEXX)
NASDAQ · Healthcare
Lexaria Bioscience Corp. EBITDA 2016–2025
Lexaria Bioscience Corp. annual/quarterly ebitda history and growth rate from 2021 to 2025. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Lexaria Bioscience Corp. ebitda for the quarter ending November 30, 2025 was -1.6 M, a 41.77% decrease year-over-year.
- Lexaria Bioscience Corp. ebitda for the twelve months ending November 30, 2025 was -7.0 M.
- Lexaria Bioscience Corp. annual ebitda for 2025 was -11.8 M, a 107.15% increase from 2024.
- Lexaria Bioscience Corp. annual ebitda for 2024 was -5.7 M, a 10.61% decrease from 2023.
- Lexaria Bioscience Corp. annual ebitda for 2023 was -6.4 M, a 1.96% decrease from 2022.
- Lexaria Bioscience Corp. annual ebitda for 2022 was -6.5 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Lexaria Bioscience Corp. EBITDA — FAQ
Lexaria Bioscience Corp. (LEXX) ebitda over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see LEXX's ebitda history?
The chart and table above show Lexaria Bioscience Corp.'s ebitda by year and by quarter, including the growth rate.